Skip to content

Sofosbuvir/Velpatasvir/Voxilaprevir

    Brands

    DEA Class; Rx

    Common Brand Names; Vosevi

    • HCV NS5A Inhibitors; 
    • HCV Polymerase Inhibitors; 
    • HCV Protease Inhibitors

    Combination oral antiviral
    Used for the treatment of chronic hepatitis C infection in treatment-experienced adults without cirrhosis or with compensated cirrhosis (Child-Pugh A)
    Risk of hepatitis B virus (HBV) reactivation has been reported in some cases resulting in fulminant hepatitis, hepatic failure, and death

    Indicated for genotype 1, 2, 3, 4, 5, or 6 previously treated with NS5A inhibitor-containing regimen

    Indicated for genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without NS5A inhibitor

    Rifampin; significantly decreases sofosbuvir, velpatasvir, and voxilaprevir serum concentrations

    • Headache (21-23%)
    • Fatigue (17-19%)
    • Diarrhea (13-14%)
    • Nausea (10-13%)
    • Asthenia (4-6%)
    • Insomnia (3-6%)

    HBV reactivation reported

    No adequate human data are available to establish whether or not sofosbuvir/velpatasvir/voxilaprevir poses a risk to pregnancy outcomes

    Unknown if distributed in human breast milk

    Adults

    400 mg/day PO for sofosbuvir; 100 mg/day PO for velpatasvir; 100 mg/day PO for voxilaprevir.

    Geriatric

    400 mg/day PO for sofosbuvir; 100 mg/day PO for velpatasvir; 100 mg/day PO for voxilaprevir.

    Adolescents

    Safety and efficacy not established.

    Children

    Safety and efficacy not established.

    Infants

    Safety and efficacy not established.

    Neonates

    Safety and efficacy not established.

    Sofosbuvir/velpatasvir/voxilaprevir

    tablet

    • 400mg/100mg/100mg